CN102920991B - Application of composition of Chinese yarn polysaccharide and Chinese yarn protein - Google Patents
Application of composition of Chinese yarn polysaccharide and Chinese yarn protein Download PDFInfo
- Publication number
- CN102920991B CN102920991B CN201210513833.9A CN201210513833A CN102920991B CN 102920991 B CN102920991 B CN 102920991B CN 201210513833 A CN201210513833 A CN 201210513833A CN 102920991 B CN102920991 B CN 102920991B
- Authority
- CN
- China
- Prior art keywords
- group
- compositions
- chinese yam
- white matter
- precipitate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Alternative & Traditional Medicine (AREA)
- Emergency Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Child & Adolescent Psychology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to an application of a composition of Chinese yarn polysaccharide and Chinese yarn protein. Summarization and analysis of a large amount of clinic observation and an animal test prove that the composition of Chinese yarn polysaccharide and Chinese yarn protein can effectively treat metabolic syndromes characterized by obesity, insulin resistance, hypertension, hyperlipidmia and fatty liver and heart and kidney damages caused by the metabolic syndromes.
Description
Technical field
The present invention relates to the purposes of the compositions of a kind of Chinese yam polysaccharide and potato white matter, specifically, the natural composition that relates to Chinese yam polysaccharide and potato white matter in preparation treatment with obesity, the metabolism syndrome that insulin resistant, type 2 diabetes mellitus, hypertension, hyperlipidemia, fatty liver are feature and due to purposes in heart and kidney damage class medicine.
Background technology
Metabolism syndrome is by obesity, particularly abdominal obesity, (triglyceride raises disorders of lipid metabolism, low density lipoprotein, LDL raises) metabolism obstacles of blood glucose (impaired glucose tolerance, type 2 diabetes mellitus) the disease group of hypertension and other some diseases composition, as far back as the fifties in last century, just have in the world some physicians to observe: obesity particularly abdominal obesity person often simultaneously with disorders of lipid metabolism, metabolism obstacles of blood glucose and hypertension, above-mentioned disease often comes across with it same patient simultaneously, and occur seldom separately, this disease group was named as rich syndrome once, X syndrome etc., a Committee of Experts of World Health Organization (WHO) in 1998 is thought through discussing, this syndromic each component disease is all relevant with metabolism, therefore finally this syndrome is unified to called after metabolism syndrome.
Metabolism syndrome has comprised the risk factor of most cardiovascular and cerebrovascular diseases, therefore effectively prevent and treatment metabolism syndrome, also just mean and not only can prevent and treat metabolism syndrome itself, also mean generation and the development that can effectively prevent cardiovascular and cerebrovascular disease, therefore, to the treatment of metabolism syndrome, there are great scientific meaning and social meaning, but up to the present still do not have a kind of medicine that can treat specifically metabolism syndrome to drop into clinical use, clinician is to being diagnosed as the individually dosed method of the general employing of patient of metabolism syndrome, to each component disease of metabolism syndrome, giving separately respectively medicine targetedly treats, therefore, the present invention has important clinical value and good market prospect.
The natural composition of Chinese yam polysaccharide and potato white matter is the active ingredient extracting from Dioscoreaceae yam Rhizoma Dioscoreae rhizome, in (patent No. ZL201010171536.1), point out that it has the effect for the treatment of sleep apnea syndrome, the present invention further studies and shows on this basis: Chinese yam polysaccharide and potato white matter compositions are for the Main Components disease of metabolic syndrome, obesity, insulin resistant, type 2 diabetes mellitus, hyperlipidemia, hypertension, fatty liver and the heart causing thereof, kidney damage has good treatment and protective effect, and Chinese yam polysaccharide and potato white matter compositions derive from natural plants, and medicine source abundance is extracted preparation method simple and easy to do, can be made into capsule, tablet, granule, oral liquor and other types of formulations, can treat the Main Components disease obesity of metabolism syndrome effectively, insulin resistant, type 2 diabetes mellitus, hyperlipidemia, hypertension, heart and kidney damage that the component disease of fatty liver and above-mentioned metabolism syndrome causes, but up to the present, there is not yet relevant report.
Summary of the invention
The object of the invention is, the purposes of the compositions of a kind of Chinese yam polysaccharide and potato white matter is provided, through a large amount of clinical observations is summarized and is analyzed, and by zoopery prove Chinese yam polysaccharide and potato white matter compositions can effectively treat metabolism syndrome take obesity, insulin resistant, hypertension, hyperlipidemia, fatty liver as feature and due to heart and kidney damage.
The purposes of a kind of Chinese yam polysaccharide of the present invention and potato white matter compositions, this Chinese yam polysaccharide and potato white matter compositions are for treating with obesity in preparation, insulin resistant, type 2 diabetes mellitus, hypertension, hyperlipidemia, fatty liver is the medicine of heart and kidney damage class due to the metabolism syndrome of feature and metabolism syndrome, the compositions of wherein said Chinese yam polysaccharide and potato white matter is the active substance extracting in Dioscoreaceae yam Rhizoma Dioscoreae or other plant of Dioscoreaceae Wild yam, it is a kind of yellowish-brown powder, the preparation method of Chinese yam polysaccharide and potato white matter compositions follows these steps to carry out:
A, Rhizoma Dioscoreae is pulverized, with Rhizoma Dioscoreae weight 2-5 water heating doubly, temperature 50-100 ℃, reflux, extract, 2-3 time, time 2-3 hour, filters, merge extractive liquid,, filtration, is concentrated into 50%;
B, concentrated solution is added to 95% ethanol, make concentrated solution contain alcohol amount and reach 30%, occur after precipitation, precipitate being removed;
C, continuation add 95% ethanol to make to reach 90% containing alcohol amount in concentrated solution, standing 3-6 hour after having precipitate to occur, after precipitate is fully precipitated, pump supernatant collecting precipitation thing, be dried again, pulverize, can obtain yellowish-brown powder Chinese yam polysaccharide content is that 40-50% and potato white matter are the compositions of content 30-40%.
Described medicine be compositions take Chinese yam polysaccharide and potato white matter as active ingredient, add the pharmaceutical preparation that acceptable carrier pharmaceutically or complementary composition are prepared from.
Content according to the present invention, according to the ordinary skill of this area and customary means, not departing under the prerequisite of the above-mentioned basic thought of the present invention, can also make the modification of other various ways, replaces and changes.
The specific embodiment of form by the following examples, is described in further detail foregoing of the present invention again, but this should be interpreted as to the scope of the above-mentioned theme of the present invention only limits to following example.All technology realizing based on foregoing of the present invention all belong to scope of the present invention.
Accompanying drawing explanation
Fig. 1 is pathological section figure of the present invention, and wherein A-1 is heart, and A-2 is liver, and A-3 is kidney; B-1 is heart, and B-2 is liver, and B-3 is kidney; CA-1 is heart, and CA-2 is liver, and CA-3 is kidney; CB-1 is heart, and CB A-2 is liver, and CB-3 is kidney.
The specific embodiment
A, by the dry rhizome of Rhizoma Dioscoreae crude drug in whole, be raw material, remove vegetable fault, take after 10 kilograms of pulverizing, by the water heating of 2 times of Rhizoma Dioscoreae weight, temperature 50 C, reflux, extract, 2 times, time 2 h, filters, and merge extractive liquid,, will be concentrated into 50% after extracting liquid filtering;
B, concentrated solution is added to 95% ethanol, make concentrated solution contain alcohol amount and reach 30%, occur after precipitation, precipitate being removed;
C, continuation add 95% ethanol to make to reach 90% containing alcohol amount in concentrated solution, there is precipitate to occur latter standing 3 hours, after precipitate is fully precipitated, pump supernatant collecting precipitation thing, be dried again, pulverize, can obtain yellowish-brown powder Chinese yam polysaccharide content is that 40-50% and potato white matter are the compositions of content 30-40%.
A, by the dry rhizome of Rhizoma Dioscoreae crude drug in whole, be raw material, remove vegetable fault, take after 10 kilograms of pulverizing, with the water heating of 5 times of Rhizoma Dioscoreae weight, 100 ℃ of temperature, reflux, extract, 3 times, 3 hours time, filter, merge extractive liquid,, filters, and is concentrated into 50%;
B, concentrated solution is added to 95% ethanol, make concentrated solution contain alcohol amount and reach 30%, occur after precipitation, precipitate being removed;
C, continuation add 95% ethanol to make to reach 90% containing alcohol amount in concentrated solution, there is precipitate to occur latter standing 6 hours, after precipitate is fully precipitated, pump supernatant collecting precipitation thing, be dried again, pulverize, can obtain yellowish-brown powder Chinese yam polysaccharide content is that 40-50% and potato white matter are the compositions of content 30-40%.
A, by the dry rhizome of Rhizoma Dioscoreae crude drug in whole, be raw material, remove vegetable fault and take after 10 kilograms of pulverizing, with the water heating of 3.5 times of Rhizoma Dioscoreae weight, 80 ℃ of temperature, reflux, extract, 3 times, 2.5 hours time, filter, merge extractive liquid,, filters, and is concentrated into 50%;
B, concentrated solution is added to 95% ethanol, make concentrated solution contain alcohol amount and reach 30%, occur after precipitation, precipitate being removed;
C, continuation add 95% ethanol to make to reach 90% containing alcohol amount in concentrated solution, there is precipitate to occur latter standing 4.5 hours, after precipitate is fully precipitated, pump supernatant collecting precipitation thing, be dried again, pulverize, can obtain yellowish-brown powder Chinese yam polysaccharide content is that 40-50% and potato white matter are the compositions of content 30-40%.
The compositions of embodiment 4 Chinese yam polysaccharides and potato white matter is tested nutritive obesity in rats effect:
Materials and methods:
Animal: health, 120 of male SD rats, weight 180-220g, Mus 3-4 in age month (Xinjiang Medicine University's Experimental Animal Center provides);
Feed formula: the high sugared semi-synthetic high-calorie feed of high fat (20% fat, 52% sucrose, 18% protein and appropriate salt-mixture, vitamin and normal feedstuff etc.) normal diet;
Tested medicine: natural composition (hereinafter referred to as the compositions) adding distil water of Chinese yam polysaccharide and protein mixes rear become medicinal liquid (every 100ml is containing compositions 25g);
Positive control drug: hydrochloric acid divides fluorine Lamine sheet (Tablets fenfl urami nehydrochloric de, TFH), specification: every hydrochloric point fluorine Lamine 20mg.Clinical dosage is each 1, every day 3 times, Baoshan Pharmaceutical Factory, Yadong medicine Corp., Shanghai medicine Industr's product, the accurate word (1995) of medicine the 035001st is defended in Shanghai, lot number 060523. is prepared: get TFH100mg adding distil water to 100mL, after mixing 0.1% medicinal liquid for positive control group, use;
Obesity rat model: animal is divided into two groups at random, Normal group is fed normal diet, and fat group is fed high-calorie feed, the equal ad lib of all rats, freely drinks water; Before experiment, after test, weigh weekly body weight one time, all at 9 o'clock in the morning, weighed.After 6 weeks, when significant difference appears in two treated animal body weight, obese model is set up;
Weight-reducing experiment: fat treated animal is divided at random: fat matched group, compositions small dose group, the heavy dose of group of compositions; Animal continues to feed high-calorie feed, and Normal group is fed normal diet, freely drink water, and feed; Gave composition solution with 10 o'clock gavage mode every mornings, low dose, 0.5ml/100g body weight, heavy dose of 1ml/100g body weight, matched group is filled with distilled water 1ml/100g body weight, and positive controls is filled with hydrochloric acid and is divided fluorine Lamine medicinal liquid 1ml/100g body weight, and experimental period is 5 weeks;
Evaluation index:
(1) body weight numerical evaluation: weigh once in a week body weight one time, all weighed at 9 o'clock in the morning;
Around kidney (2), abdominal cavity fat gravimetry: put to death after blood-letting, cut open respectively get kidney around and intraperitoneal all fatty, take weight in wet base;
Statistical method: adopt on computers SPSS to carry out statistical disposition, dosage data represents with x ± S;
Result:
The impact of compositions on obese rat body weight:
As shown in table 1, when modeling finishes, model group rat body weight (456.7 ± 10.9) exceeds 19%(P < 0.05 than normal saline group), illustrate that model is successfully established; After administration one month, large and small two the dosage group rat body weights of compositions (437.5 ± 18.0 and 405.3 ± 28.4) obviously decline compared with (464.3 ± 10.9) before administration and (422.3 ± 23.8), do not treat obviously rising (456.7 ± 10.9 to 484.6 ± 8.8) of model group.Abdominal cavity fat weight in wet base is remarkable reduction compared with matched group, in Table 2
The impact (g) (mean ± SE) of table 1 compositions on obese rat body weight
Body weight and abdominal cavity fat weight before and after the treatment of the each group of table 2 rat (x ± s)
The experiment of the compositions of embodiment 4 Chinese yam polysaccharides and potato white matter to diabetic mice effect due to STZ:
Materials and methods:
Animal: WISTAR rat, 135g-180g, male, Xinjiang Medicine University's zoopery center provides;
Main agents and equipment: streptozotocin (STZ), Sigma company; Trace Instrument for Measuring Blood Sugar, the supporting blood sugar test paper of German Roche ACCU-CHEK Advantage II();
STZ liquid preparation: STZ is dissolved in to (ph 4.5) in 0.1mol/L trisodium citrate 2 citrate buffer solutions, making concentration is the STZ liquid of 10mg/ml, and wherein trisodium citrate 2 citrate buffer solutions are by 1:1.32 volume formulated [1] by 0.1mol/L trisodium citrate mother solution and 0.1mol/L citric acid mother liquor;
Laboratory animal grouping and model are set up: experimental group rat is dissolved in PH 4.5 by the disposable injection STZ in 60mg/kg abdominal cavity, 0.1mol/L citrate buffer, and concentration is 2%.Matched group only gives equivalent citrate buffer, after 72h, through rat tail vein blood sampling, surveys blood glucose, using random blood sugar higher than 16.7mmol/L as diabetes model success standard [2].Diabetes model is set up rear rat and is divided into T group: 10 every group;
A group is physiology saline control group, B group is diabetes model matched group, C group is diabetic composition low dose (0.21g/kg/d) treatment group, D group is diabetic composition heavy dose (0.42g/kg/d) treatment group, E group for diabetes Insulin (2-4IU/ only/d) treatment group, A, two groups of gavages of B give pure water, C, D two groups of every days, gavage was equivalent to Chinese yam polysaccharide and potato white matter compositions (abbreviation compositions) solution of 0.21g/kg/d and 0.42g/kg/d respectively;
Laboratory animal sign index detects: after lumbar injection STZ solution the 3rd, 7,14,21d and 30d measure the blood glucose of each treated animal respectively, after injection STZ3d, animal blood glucose concentration > 16.65mmol/L is judged to be diabetes animal model, blood specimen collection adopts the tail method of cutting, by rapid blood sugar algoscopy mensuration;
Serum insulin levels measured by radioimmunoassay;
Statistical analysis: all data acquisitions SPSS10.0 software analysis, measurement data data are so that (x ± s) represents, between many groups, mean relatively adopts t check;
Result: insulin resistant refer to body to the biological effect of a certain amount of insulin lower than estimating a kind of phenomenon of normal level, in this experiment in model control group and compositions treatment group blood insulin content without significant difference, but it is nearly 50% that the compositions treatment group blood sugar level of Chinese yam polysaccharide and potato white matter has reduced than model control group blood sugar level, illustrates that insulin resistant and type 2 diabetes mellitus can be treated and improve to the compositions of Chinese yam polysaccharide and potato white matter effectively;
Table 3 compositions is to blood glucose and insulin content in STZ induced Diabetic rat blood
Table 4 experimental session is respectively organized experimental rat change of blood sugar situation
The SHR(transgenic essential hypertension of the compositions of embodiment 5 Chinese yam polysaccharides and potato white matter to fed with high) the effect experimentation of rat:
Material:
Laboratory animal: 60 of healthy regular grade SHR rats, male, in 12 week age, body weight (267.48 ± 7.62) g, purchased from Beijing Vital River Experimental Animals Technology Co., Ltd.;
Feedstuff: normal diet is Growth in Rats standard recipe idiophase; High lipid food formula is: large oil 10%, cholesterol 2%, cholate 0.5%, white sugar 15%, Oleum sesami 0.5%, normal feedstuff 67%, Jun You Xinjiang Medicine University Experimental Animal Center processing and fabricating;
Experiment key instrument:
(1) BP-6 noinvasive animal blood pressure measuring system, Chengdu TME Technology Co., Ltd. produces;
(2) blood sugar test paper and rapid blood sugar are bought at negotiated prices from Johnson Co.;
(3) AUTOLAB PM400/3 full automatic biochemical apparatus: Italy produces;
(4) DM2500 microscope: Leca company;
(5) LEICA RM2235 microtome: Leca company;
(6) BMJ-1 biological tissue embedding machine: Tianli Aeronautics Electromechanical Co., Tianjin;
(7) TSJ-IA automatic tissue hydroextractor: Tianli Aeronautics Electromechanical Co., Tianjin;
(8) the roasting sheet machine of KZPJ-IA biological tissue stand sheet: Tianli Aeronautics Electromechanical Co., Tianjin;
(9) TDL-40B desk centrifuge: Anting Scientific Instrument Factory, Shanghai manufactures.
Main agents box:
1) triglyceride (TG): measure lot number: 2011907 according to test kit description enzymic colorimetric (GPO-PAP method).
2) T-CHOL (CHO): measure lot number: 2011907 according to test kit description enzymic colorimetric (CHOD-PAP method).
3) low density lipoprotein, LDL (LDL): measure lot number: 2011907 according to test kit description urase continuous detecting method.
4) high density lipoprotein (HDL): measure lot number: 2011907 according to test kit description urase continuous detecting method.
Above test kit factory is Zhongsheng Beikong Biological Science & Technology Co., Ltd., operative norm number: word YZB/ state 2089-2003.
5) rat aorta Angiotensin Converting Enzyme II ELISA test kit, Xi Tang bio tech ltd, Shanghai, lot number: 1109252
Main medicine: Chinese yam polysaccharide and potato white matter compositions (hereinafter to be referred as compositions).
Experimental technique and step: 60 male spontaneous hypertensive rats are divided into normal diet+normal saline group (A group), high lipid food+normal saline (B group), high lipid food+compositions 200mg/kg (CA group), high lipid food+compositions 400mg/kg (CB group) at random, normal SD rats (normal diet+normal saline group) (D group), gastric infusion, be administered once every day, successive administration 8 weeks, matched group is given normal saline, periodic logging body weight, measures blood pressure once in a week;
Experimental observation index and assay method:
Blood pressure determination: under waking state, the morning, for 8:00-12:00., tail-cover method was measured the systolic blood pressure of rat; Measure blood pressure is used the arteria caudalis method of heating: through the pre-benign environment of afterbody, adapt to, make rat heart rate stable, experimental mouse is put into and is adjusted in the temperature control box of 40 ℃ about 5 minutes, put into again the rat fixator that remains on 37 ℃ of constant temperature of temperature, the tail that exposes experimental mouse is measured systolic pressure, during each measuring blood pressure, 15 blood pressure readings of continuous record, cast out the highest and minimum, and on average other 3 values are as inferior pressure value;
The detection of blood biochemistry index: press test kit description and measure T-CHOL (TC), triacylglycerol (TG), low-density lipoprotein cholesterol (LDL) and HDL-C (HDL);
The mensuration of organ index: detect liver exponential sum kidney weight, and by liver, kidney, the fixing 24h of 10% paraformaldehyde for heart and ventral aorta, paraffin embedding, makes the thick pathological section of 3 μ m, conventional dewaxing, dehydration, HE dyeing, light Microscopic observation does histopathology to be changed; Statistical procedures: enumeration data is so that (x ± s) represents, all experimental datas all adopt SPSS statistical software to carry out statistical analysis; Before and after in each group, change and relatively adopt paired data t check; Between group, lateral comparison quantitative data adopts variance analysis;
Result: reduce when CA group and CB blood pressure are tested beginning when experiment finishes when A group and B group pressure value start and raise, blood Angiotensin-Converting content CA group and CB group are organized compared with A and B group significantly reduces; CA group and CB group blood fat (triglyceride, T-CHOL, low density lipoprotein, LDL) all have remarkable reduction compared with A group and B group;
Histopathological findings (accompanying drawing):
A-1 heart: myocardial cell arrangement disorder, muscle fiber increases thick loose, and cardiac muscle fiber interval is strengthened, and part cardiac muscle fiber fracture, is shown in focal necrosis, and myocardium interstitial collagen fiber increases;
A-2 liver: matched group liver outward appearance is not abnormal, light Microscopic observation matched group liver rope and sinus hepaticus clear in structure, cell is streak arrangement, core rounding;
A-3 kidney: the obvious hypertrophy of mesangial cell, glomerular capillary dilatation and congestion, renal cells swelling, renal cells is treating serious edema caused, and glomerule ductus arteriosus wall thickens, the interstitial congestion of blood vessel, capillary basement membrane thickens, and mesangial cell increases;
B-1 heart: myocardial cell arrangement disorder, cardiac muscle fiber increases thick loose, and cardiac muscle fiber interval is strengthened, part cardiac muscle fiber fracture, the dyeing of part myocardial cell cytoplasm is deepened, and nucleus is concentrated, see focal necrosis, myocardium face has petechia, and in tissue, visible inflammatory cell is invaded profit;
B-2 liver: liver color shoals, and severe patient is yellow-white, part liver irregular colour is graniphyric, the visible needle point in surface is to Semen Glycines size yellow-white degeneration kitchen range, part liver enlarges markedly, peplos anxiety, and edge is blunt, the visible infarct of only a few liver, hepatocyte normal morphology disappears, obscurity boundary, and fat distortion is serious, almost in whole hepatocyte, be full of large blister fat and drip cavity, severe patient is downright bad to be merged in flakes;
B-3 kidney: glomerular capillary dilatation and congestion, renal cells is treating serious edema caused, and renal tubules arterial wall thickens, the interstitial congestion of blood vessel, the obvious hypertrophy of mesangial cell, mesangial cell increases;
CA-1 heart: myocardial cell is slightly loose, arranges more neat;
CA-2 liver: liver color shoals lighter.Hepatocyte normal morphology disappears lighter, and enlargement is not obvious, central vein and interstitial vasodilation hyperemia, and it is not obvious that fat is invaded profit;
CA-3 kidney: glomerular capillary dilatation and congestion, kidney blood vessel epithelial cell Mild edema, renal tubules arterial wall slightly thickens, interstitial hyperemia, hypertrophy that mesangial cell is slight, most blood capillaries are open;
CB-1 heart: myocardial cell is slightly loose, arranges more neat;
CB-2 liver: liver color shoals lighter, part of hepatocytes enlargement edema, central vein and interstitial vasodilation hyperemia, fatty infiltration is not obvious;
CB-3 kidney: dilatation and congestion that glomerular capillary is slight, renal tubules arterial wall slightly thickens, and glomerule arterial wall slightly thickens, and most blood capillaries are open, and mesangial cell and extracellular matrix have no and increase and hypertrophy;
The impact of table 5 compositions on liver, renal index
| Grouping | Dosage (mg/kg) | Liver index | Renal index |
| A group | ----- | 3.46±0.23* | 0.79±0.03 |
| B group | ----- | 4.09±0.21 | 0.71±0.04 |
| CA group | 200 | 3．4±0.31* | 0.72±0.03 |
| CB group | 400 | 3．49±0.35* | 0.68±0.02 |
Note: with relatively * P < 0.05 of model group (SHR+ is high), * * P < 0.05
The impact of table 6 compositions on rat blood pressure
| Grouping | Dosage (mg/kg) | BP (June 28) | BP ( |
| A group | ----- | 150.59±4.08 | 167.25±2.24 |
| B group | ----- | 156.99±2.76 | 167.82±2.86 |
| CA group | 200 | 158.17±4.80 | 153.41±8.0* |
| CB group | 400 | 161.38±2.91 | 159.19±7.00 |
| D group | ----- | 102.38±2.38 | 106.69±1.81 |
Note: with relatively * P < 0.05 of model group (SHR+ is high), * * P < 0.05
The impact of table 7 compositions on rat blood serum angiotensin
| Grouping | Dosage (mg/kg) | AgII（pg/ml） |
| D group | ----- | 81.5±15.16 |
| A group | ----- | 411.67±115,81** |
| B group | ? | 480．67±62.33 |
| CA group | 200 | 308.40±156.40# |
| CB group | 400 | 316.67±145.00△ |
Note: with relatively * P < 0.05 of model group (SHR+ is high), * * P < 0.05
The impact of table 8 compositions on rat fat
Note: with relatively * P < 0.05 of model group (SHR+ is high), * * P < 0.05.
Claims (1)
- Chinese yam polysaccharide and potato white matter compositions in preparation treatment the purposes in the medicine of heart and kidney damage class due to the metabolism syndrome take obesity, insulin resistant, type 2 diabetes mellitus, hypertension, hyperlipidemia, fatty liver as feature and metabolism syndrome, the preparation of described Chinese yam polysaccharide and potato white matter compositions follows these steps to carry out:A, by the dry rhizome of Rhizoma Dioscoreae crude drug in whole, be raw material, remove vegetable fault and take after 10 kilograms of pulverizing, with the water heating of 3.5 times of Rhizoma Dioscoreae weight, 80 ℃ of temperature, reflux, extract, 3 times, 2.5 hours time, filter, merge extractive liquid,, filters, and is concentrated into 50%;B, concentrated solution is added to 95% ethanol, make concentrated solution contain alcohol amount and reach 30%, occur after precipitation, precipitate being removed;C, continuation add 95% ethanol to make to reach 90% containing alcohol amount in concentrated solution, there is precipitate to occur latter standing 4.5 hours, after precipitate is fully precipitated, pump supernatant collecting precipitation thing, be dried again, pulverize, can obtain yellowish-brown powder Chinese yam polysaccharide content is that 40-50% and potato white matter are the compositions of content 30-40%.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210513833.9A CN102920991B (en) | 2012-12-05 | 2012-12-05 | Application of composition of Chinese yarn polysaccharide and Chinese yarn protein |
| PCT/CN2013/088333 WO2014086255A1 (en) | 2012-12-05 | 2013-12-02 | Use of composition of yam polysaccharides and yam proteins |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210513833.9A CN102920991B (en) | 2012-12-05 | 2012-12-05 | Application of composition of Chinese yarn polysaccharide and Chinese yarn protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102920991A CN102920991A (en) | 2013-02-13 |
| CN102920991B true CN102920991B (en) | 2014-05-07 |
Family
ID=47636016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210513833.9A Expired - Fee Related CN102920991B (en) | 2012-12-05 | 2012-12-05 | Application of composition of Chinese yarn polysaccharide and Chinese yarn protein |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN102920991B (en) |
| WO (1) | WO2014086255A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102920991B (en) * | 2012-12-05 | 2014-05-07 | 多力坤·马木特 | Application of composition of Chinese yarn polysaccharide and Chinese yarn protein |
| CN113101333A (en) * | 2021-04-27 | 2021-07-13 | 河南理工大学 | Application of dioscorea opposita thumb extract as only effective component in preparation of products for preventing and treating obesity |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810636A (en) * | 2010-05-13 | 2010-08-25 | 多力坤·马木特 | Application of Chinese yam polysaccharide in preparation of medicament for treating obesity |
| CN101822818A (en) * | 2010-05-13 | 2010-09-08 | 多力坤·马木特 | Composition of Chinese yam polysaccharide and Chinese yam protein and application thereof |
| CN101890152A (en) * | 2010-05-13 | 2010-11-24 | 多力坤·马木特 | Application of Chinese yam glycoprotein in preparation of antihypoxic and antifatigue medicaments |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101348819B (en) * | 2007-07-16 | 2012-02-22 | 天津科技大学 | Technology for extracting Chinese yam protein complex by enzyme method |
| CN102920991B (en) * | 2012-12-05 | 2014-05-07 | 多力坤·马木特 | Application of composition of Chinese yarn polysaccharide and Chinese yarn protein |
-
2012
- 2012-12-05 CN CN201210513833.9A patent/CN102920991B/en not_active Expired - Fee Related
-
2013
- 2013-12-02 WO PCT/CN2013/088333 patent/WO2014086255A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810636A (en) * | 2010-05-13 | 2010-08-25 | 多力坤·马木特 | Application of Chinese yam polysaccharide in preparation of medicament for treating obesity |
| CN101822818A (en) * | 2010-05-13 | 2010-09-08 | 多力坤·马木特 | Composition of Chinese yam polysaccharide and Chinese yam protein and application thereof |
| CN101890152A (en) * | 2010-05-13 | 2010-11-24 | 多力坤·马木特 | Application of Chinese yam glycoprotein in preparation of antihypoxic and antifatigue medicaments |
Non-Patent Citations (4)
| Title |
|---|
| 山药多糖对2型糖尿病大鼠肾病的预防作用研究;杨宏莉;《中国药房》;20121231;第21卷(第15期);第1345-1346页 * |
| 山药多糖的提取分离及活性初步研究;高英春;《中国优秀硕士学位论文全文数据库》;20090915;第1-23页 * |
| 杨宏莉.山药多糖对2型糖尿病大鼠肾病的预防作用研究.《中国药房》.2012,第21卷(第15期),第1345-1346页. |
| 高英春.山药多糖的提取分离及活性初步研究.《中国优秀硕士学位论文全文数据库》.2009,第1-23页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102920991A (en) | 2013-02-13 |
| WO2014086255A1 (en) | 2014-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102090630B (en) | Health-care product for enhancing antioxidation of human bodies and preparation method thereof | |
| CN101091765A (en) | Medicinal comsns-and usage for preventing and treating diabets mellitus | |
| CN107441078B (en) | A kind of pharmaceutical composition and its preparation method and application for treating diabetes | |
| Adeneye et al. | Further evaluation of antihyperglycaemic activity of Hunteria umbellata (K. Schum) Hallier f. seed extract in experimental diabetes | |
| CN102920991B (en) | Application of composition of Chinese yarn polysaccharide and Chinese yarn protein | |
| CN106138210A (en) | Butterflybush flower and the application of the medicine as preparation treatment hypertensive cardiopathy for the extract thereof | |
| CN104523742B (en) | A kind of polysaccharide composition and its application with protect liver and raising immunization | |
| CN101336974B (en) | Traditional Chinese medicine for reducing blood sugar and regulating lipid with overall regulation of body metabolism and preparation method thereof | |
| CN107073060B (en) | Aqueous extracts of cinnamon and astragalus | |
| EP1369123A1 (en) | A health-care product comprising lotus rhizome and process for its preparation | |
| Abbas et al. | Possible antidiabetic mechanism of action of ex-maradi okra fruit variety (Abelmoscus esculentus) on alloxan induced diabetic rats | |
| CN101167781A (en) | Orally-administered hypoglycemic sweet potato leaf single prescription traditional Chinese medicine and preparation method thereof | |
| CN103222995A (en) | Application of gynura divaricata in preparing liver-protecting drug or health-care food | |
| CN1315499C (en) | Medicine for treating diabetes and its complications and process for preparing the same | |
| CN108524811A (en) | Reduce uric acid, cholesterol, three high Chinese medicine compositions and its preparation method for the treatment of | |
| CN109381455A (en) | With the composition for adjusting blood glucose, blood lipid and blood pressure function | |
| Gupta et al. | Effect of germinated Glycine max seeds on glycemic control in STZ+ NAD induced type 2 diabetic models: a preliminary study. | |
| CN101269152A (en) | Application of matrimony vine and black fungus in preparing fatty liver resistant medicament | |
| CN111991449A (en) | Traditional Chinese medicine composition for preventing and treating heart failure with preserved ejection fraction and preparation method thereof | |
| CN101167887A (en) | Orally-administered matrimony vine single preparation traditional Chinese medicine for treating diabetes and preparation method thereof | |
| CN105535070B (en) | The pharmaceutical composition and its preparation method and application for treating diabetes | |
| CN110507759A (en) | A kind of three yellow Chinese herbal preparation of particles and preparation method thereof with control hyperglycemia | |
| CN102430001B (en) | Compound rose-hip flavone preparation for preventing diabetes mellitus and preparation method thereof | |
| CN101843763B (en) | Traditional Chinese medicine capable of treating complicated symptom of diabetes and stagnant heat and application thereof | |
| CN105232676B (en) | A kind of Chinese medicine for treating diabetes and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160414 Address after: 830002, the Xinjiang Uygur Autonomous Region, Tianshan District, Yanan Road, No. 154, Urumqi, Tian An small high 5, 2, 2 shops Patentee after: Xinjiang Lemei biotechnology Ltd. Address before: 830002 No. 496 Xinhua South Road, the Xinjiang Uygur Autonomous Region, Urumqi Patentee before: Duolikun.Mamute |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140507 Termination date: 20211205 |